Galantos Pharma GmbH, a Mainz, Germany-based developer of innovative medication for neurodegenerative diseases with a focus on Alzheimer’s dementia, has raised €4.4m (approximately US$ 5.7m) in a Series C financing round.
Investors include VRP (Rhineland Palatinate Fund), KfW (German State Bank), FIB (Investment Bank Rhineland Palatinate), WFT (Venture Fund Rhineland Palatinate), and HTGF (High-Tech Fund).
The BMBF (German Ministry for Education and Research) provided the company with public funds.
The funds will be used to bring the company’s leading compound Memogain® for Alzheimer’s Dementia (AD) into the clinic and to develop novel neuroprotective AD compounds.
FinSMEs
04/05/2010